Venus Concept extends loan maturity and receives liquidity waivers

Venus Concept Inc. (NASDAQ:VERO), a medical technology company with a market capitalization of $4 million and current debt of $37 million, reported Wednesday that it entered into several agreements with its lenders to adjust terms on existing debt facilities. The company, which has seen its stock decline 47% year-to-date, disclosed the changes in a statement based on a filing with the Securities and Exchange Commission. According to InvestingPro analysis, the company’s overall Financial Health Score is currently rated as WEAK.

On August 31, Venus Concept Inc. and its subsidiaries signed a Consent Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP. The agreement waives certain minimum liquidity requirements under the company’s Main Street Priority Loan Agreement through September 30, 2025.

Also on August 31, Venus Concept and its subsidiaries executed the Nineteenth Bridge Loan Amendment Agreement with the same lenders. This amendment extends the maturity date of the company’s Bridge Loan from August 31, 2025 to September 30, 2025.

In a related move, Venus Concept and its subsidiaries entered into a Consent Agreement with the lenders regarding its secured subordinated convertible notes issued on March 31, 2025. This agreement also waives certain minimum liquidity requirements under the notes through September 30, 2025.

These agreements involve Venus Concept Inc., Venus Concept USA, Inc., Venus Concept Canada Corp., and Venus Concept Ltd., with Madryn Health Partners, LP and its Cayman affiliate acting as lenders.

The company stated that the descriptions of these agreements are qualified in their entirety by reference to the full texts, which have been filed as exhibits to the SEC filing.

Venus Concept Inc. is listed on the Nasdaq Capital Market under the ticker VERO. The information in this article is based on a press release statement and an SEC filing.

In other recent news, Venus Concept Inc. reported its financial results for the second quarter of 2025, showing a 5% decline in total revenue to $15.7 million compared to the previous year. The company also experienced a net loss of $11.7 million, which translates to $8.03 per share, and an adjusted EBITDA loss of $8.8 million. Despite these financial challenges, Venus Concept is undertaking strategic initiatives, including a planned product launch slated for early 2026 and exploring opportunities in the weight loss sector. The company has not provided full-year guidance for 2025. Additionally, Venus Concept secured an extra $2 million in bridge financing under its existing loan and security agreement. This financing was obtained through the eleventh drawdown with lenders Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP. The loan carries an interest rate of 12% per annum and is backed by a priority security interest in all real and personal property collateral of the company and its subsidiaries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.